Get 40% Off
💎 WSM is up +52.1% since our AI picked it in December! Unlock all premium stock picksUnlock now

GSK plc (GSK)

London
Currency in GBP
Disclaimer
1,709.20
+4.00(+0.24%)
Real-time Data

GSK Comments

BRIEF-Hedge Fund Elliott Builds Up Multi-billion-pound Stake In UK's GSK - Ft
TO THE MOON!
It dropped quickly from 15 to 12. Now only 13.5. The rise for one day doesn't mean much
PE is 11 still cheap.
It dropped quickly from 15 to 12. Now only 13.5. The rise for one day doesn't mean much
I bought at 12.15 on 4th March. Looking forward after all this time waiting!
going to 20
20 what?
not going to 20 anytime soon unfortunately, years away
nice, going to moon now, too late for those who didnt buy under 13
It's a bargain atm. Big solid company, great div and plays as a safe haven. Price is far below average consensus, so there is a room to raise.
Don't count on the dividend because they will cut it soon
Who says?
According to my data, there's still significant short interest on GSK. They might try to run stops on low volume to get the price down.
I fear we wil fall till the 13s back soon
Why sell? Don't like the great products or generous dividend? Don't get the trade idea for shorting / selling here....
Green at the of the day
Target price £14.00
great news about covid vaccine...GSK: -0.58%. LOL this stock is dead, I`m out today.
I bought at £12.15 I hope this value improves soon!
Downgraded to underperforming
By the short sellers?
Buy rating by Goldman Sachs
with the news for medicago & gsk covid vaccine, i am seeing this back to 14
value trap at moment; not a fan of Walmsley. However a) mainstream pharma suffering from covid due to all other medicines / ops delayed due to hospitals filled with covid b) other vaccines delayed due to to covid (& GSK are no 1 in world on vaccines) c) they didnt go into covid vaccine early on as they chose to licence their IP to others on how to make them stable for the elderly and at higher temperatures.  So this is likely to recover coming out of covid so its a 1/2 year hold sadly?
I like your opinion. Any guess on the bottom or will it float around here
 Hi, sorry... dont often look at GSk... I think it is close to the bottom and will consolidate here at least until end April when Q1 2021 data comes out. I cannot imagine this will be great and the year ago comparison will still be bad. Also the board are all selling shedloads at these prices which is concerning.  But the 9 day moving ave looks as if it will go through the 26 day moving ave to the upside shortly.  If i didn't have any i think i'd wait a bit longer for Q1 results; if you have some, be prepared to wait a year is my honest view.
Someone wake up this stock. GSK is sleeping (and drowning)
Very harsh article form seeking Alpha on GSK. Presented as a fact that  GSK will conduct value destroying acquisitions. Guidance evidently given by management.  I LIKE to be an contrarian and would BUY the stock below 13 GBP in size. See whos right, Seeking Alpha or Tomas.
GSK is proving to be a train crash under Walmsley. Latest in the mediocre performance is that it's covid vaccine alliance with Sanofi doesn't work so won't have an offering in 2021. About time Walmsley was shown the door.
Lol who are you? keep selling I Will keep buying. thank you
Like you I'm buying. GSK is a great company stuck in the slow lane due to management by committee. It's break up value is equivalent to at least £18/share (perhaps £20+ if you factor not paying a dividend). So I doubt Walmsley will get to separately list GSK as consumer and research, a more dynamic suitor will bid with much the same outlook. Shame really, a better management team should be able to pump up GSKs outlook without breakup. As I said, managerial train crash.
you have no idea how right you - managed by amateurs under the disguise of professionals is my take - and its an understatment
I find difficult that this will break resistance, there are not many better bets out there IMHO
the decline is driven by the many unknowns surrounding the company split. if you check the earnings for 2020, they are actually not bad. the outlook for 2021 might be too conservative and it could surprise to the upside.
missed revenue targets and predicting further revenue drop next year
 *earnings not revenue, sorry
 ok, but where did you see that?
 In the results, out yesterday: https://www.hl.co.uk/shares/stock-market-news/company--news/glaxosmithkline-forecasts-decline-in-2021-earnings,-shares-slump
I think this over reaction is good for this stock, it’ll attract more dividend investors who are searching solid dividend stock
 Really? Where did you see that?
 The forecast is basically flat on 2022, remember tgat stocks are very forward looking as well.
 In their results - keeping it the same this year and then reassessing dividend policy for next year.
they increased the dividend!
No they kept it the same and will cut next year
 Yes, circa 0.5 cut complessive in the forthcoming years. In line with revenue predictions. But still a very good dividend though
what happened with this company actually?
It's just that people now dump money on EVs, green energy, technology. They think that we are having some disruptive revolution in technology as we speak
why the price in pounds sterling is 12.85 and in NYSE dollars: GSK 35.42 (25.92 gbp)? 2:1?
Good time to buy
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.